Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On December 15, 2025, Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm focusing on innovative therapies for inflammatory and immune-mediated diseases, announced the granting of inducement equity awards to a newly hired non-executive officer. The awards, structured as non-qualified stock options, allow the purchase of 206,000 shares of the company’s common stock at an exercise price of $3.23 per share, with a maximum term of ten years.

The inducement awards are designed to serve as a vital incentive for the new hire’s employment, approved by Shattuck’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule permits 25% of the options to vest by November 17, 2026, with the remaining options vesting in equal monthly installments over the subsequent 36 months. Although these stock options are granted outside of the 2020 Equity Incentive Plan, they adhere to similar terms and conditions as awards under that plan.

Shattuck Labs is recognized for its development of groundbreaking therapies, particularly focusing on tumor necrosis factor (TNF) superfamily receptors. The company aims to address unmet medical needs, including a potential first-in-class antibody targeting inflammatory bowel disease (IBD) and various other inflammatory conditions. One of its leading initiatives, SL-325, is a DR3 antagonist antibody designed to provide a comprehensive blockade of the DR3/TL1A pathway, which has been clinically validated.

With operations in Austin, Texas, and Durham, North Carolina, Shattuck Labs seeks to innovate in the realm of biotechnology with a commitment to improving patient outcomes. For further information, stakeholders may contact Andrew R. Neill, Chief Financial Officer, through their investor relations email.

Shattuck Labs, Inc. (NASDAQ: STTK) recently made headlines with the announcement of inducement grants under NASDAQ Listing Rule 5635(c)(4). The company granted non-qualified stock options to a newly hired non-executive officer, totaling 206,000 shares with an exercise price of $3.23 each. This strategic move may signal a commitment to driving growth and innovation, especially in the pivotal field of therapeutic development for inflammatory and immune-mediated diseases.

Given that the options have a maximum term of 10 years and a vesting schedule that incentivizes long-term involvement, it represents not just a recruitment tactic but also a sign of confidence in the company’s potential. Investors may view this as a strong indicator of management's optimism regarding Shattuck's future prospects, particularly as it develops SL-325, a novel antibody targeting inflammatory bowel disease and other conditions.

From a market analysis perspective, the stock's exercise price at $3.23 suggests that there is potential for significant upside, particularly if Shattuck’s clinical programs progress favorably. Given the company's focus on a first-in-class approach to targeting the DR3/TL1A pathway, successful trials could lead to substantial valuation increases, benefiting current and prospective investors.

However, while the inducement grants showcase progress, investors should be cautious. The biotechnology sector is inherently volatile, with regulatory approvals and trial results playing critical roles in stock performance. It would be prudent for investors to monitor clinical trial results closely, as well as broader market trends affecting biotechnology companies.

In conclusion, Shattuck Labs may offer substantial long-term investment potential, but potential stakeholders should consider both the inherent risks and the company’s transformative potential in the realms of immunology and inflammatory diseases.